Clinical effect and mechanism of tofacitinib in the treatment of refractory lupus nephritis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065620

Enrollment

Unknown

Registered

2022-11-10

Start date

2022-11-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lupus nephritis

Interventions

Treatment group:tofacitinib in the treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis was in accordance with the classification criteria of SLE revised by the American College of Rheumatology (ACR) in 1997; 2. There is clinical evidence of renal involvement; 3. After induction remission therapy (at least one traditional immunosuppressant therapy) > 6 months, 24-hour urinary protein > 0.5g, or ln relapsed again after clinical remission.

Exclusion criteria

Exclusion criteria: 1. The patient had other autoimmune diseases, including rheumatoid arthritis, Sjogren's syndrome, and dermatomyositis; 2. There were acute infections, including upper respiratory tract infection, lung infection, urinary tract infection, etc.; 3. History of malignant tumor; 4. History of tuberculosis infection.

Design outcomes

Primary

Measure	Time frame
24-hour urine protein;eGFR;	—

Countries

China

Contacts

Public ContactZongwen Shuai

The First Affiliated Hospital of Anhui Medical University

shuaizongwen@ahmu.edu.cn+86 13956050659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026